Avascular necrosis following bone marrow transplantation: a case-control study.
The role of specific immunosuppressive agents in the development of avascular necrosis (AVN) following hematopoietic stem cell and solid organ transplantation remains unclear. To further explore this question, we conducted a case-control study of patients who underwent bone marrow transplantation (BMT) at the Fred Hutchinson Cancer Research Center. 96 of 1939 long-term survivors transplanted between May 1976 and October 1993 were identified as having AVN. Eight patients were excluded because AVN developed before transplant and one was excluded due to restrictions on reviewing follow-up records. The remaining 87 patients developed AVN a mean of 26.3 +/- 2 months posttransplant and were matched for age, gender, and date of transplant to other BMT recipients. Records were reviewed for corticosteroid and cyclosporine use, pretransplant conditioning with total body irradiation (TBI), and other information including disease for which the transplant was indicated, type of transplant, the occurrence of acute and chronic graft-vs.-host disease, and steroid use prior to transplant. Adjusted odds ratios (ORs) were obtained from conditional logistic regression for 87 matched pairs. Posttransplant steroid use was a risk factor for the occurrence of AVN (adjusted OR, 14.4; 95% CI, 2.8-73.2), with the greatest risk associated with those receiving steroids at the time of diagnosis of AVN (adjusted OR, 31.9; 95% CI, 4.4-248.9). There was no further increasing risk associated with increasing duration of steroid use. Conditioning with TBI was also associated with the occurrence of AVN (adjusted OR, 3.2; 95% CI, 1.1-9.7); however, cyclosporine was not a risk factor for AVN (adjusted OR, 0.5; 95% CI, 0.1-1.9). Our results support the hypothesis that AVN following BMT has a strong association with the administration of corticosteroids. TBI may be an additional risk factor, and cyclosporine does not appear to contribute to an increased incidence of AVN.
Fink
J C
JC
Department of Medicine, University of Maryland, Baltimore 21201, USA. jfink@umppal.ab.umd.edu
Leisenring
W M
WM
Sullivan
K M
KM
Sherrard
D J
DJ
Weiss
N S
NS
D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D001842:Bone and Bones / Q000276:immunology / Q000473:pathology; D016022:Case-Control Studies; D016572:Cyclosporine / Q000276:immunology / Q000494:pharmacology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000276:immunology / Q000494:pharmacology; D008297:Male; D016017:Odds Ratio; D010020:Osteonecrosis / Q000209:etiology* / Q000473:pathology; D012307:Risk Factors; D013256:Steroids / Q000276:immunology / Q000494:pharmacology; D014916:Whole-Body Irradiation
D007166:Immunosuppressive Agents; D013256:Steroids; D016572:Cyclosporine